Jim Cramer on ImmunityBio: “I Would Encourage You to Own It, Provided You Don’t Own Any Other Spec”

Jim Cramer gave top insight on ImmunityBio, Inc. (NYSE:IBRX), sharing a game plan of what to buy, sell, and hold right now. When a caller mentioned that they have a small position in the stock, Cramer commented:

Okay, that is a pure spec…. I would encourage you to own it, provided you don’t own any other spec, because that company is losing a lot of money.

ImmunityBio, Inc. (NASDAQ:IBRX) develops therapies designed to strengthen the immune system against infectious diseases and several cancers. A caller asked about the stock during the March 19 episode’s lightning round, and Cramer replied:

ImmunityBio had a big cross of a huge amount of stock, but at the end, I don’t know where that stock went to. I’d like to see the stock come in and see if that block holds before I buy that, because that stock is part of the magical thinking era.

While we acknowledge the risk and potential of IBRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than IBRX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.